FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma by Koole, Koos et al.
  
 University of Groningen
FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and
Oropharyngeal Squamous Cell Carcinoma
Koole, Koos; Clausen, Martijn J. A. M.; van Es, Robert J. J.; van Kempen, Pauline M. W.;
Melchers, Lieuwe J.; Koole, Ron; Langendijk, Johannes A.; van Diest, Paul J.; Roodenburg,
Jan L. N.; Schuuring, Ed
Published in:
Molecular diagnosis & therapy
DOI:
10.1007/s40291-016-0204-5
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Koole, K., Clausen, M. J. A. M., van Es, R. J. J., van Kempen, P. M. W., Melchers, L. J., Koole, R., ...
Willems, S. M. (2016). FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity
and Oropharyngeal Squamous Cell Carcinoma. Molecular diagnosis & therapy, 20(4), 363-374.
https://doi.org/10.1007/s40291-016-0204-5
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
ORIGINAL RESEARCH ARTICLE
FGFR Family Members Protein Expression as Prognostic
Markers in Oral Cavity and Oropharyngeal Squamous Cell
Carcinoma
Koos Koole1,2 • Martijn J. A. M. Clausen3,4 • Robert J. J. van Es2 •
Pauline M. W. van Kempen5 • Lieuwe J. Melchers4 • Ron Koole2 •
Johannes A. Langendijk6 • Paul J. van Diest1 • Jan L. N. Roodenburg4 •
Ed Schuuring3 • Stefan M. Willems1,7
Published online: 9 June 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Introduction Fibroblast growth factor receptor family
member proteins (FGFR1–4) have been identified as
promising novel therapeutic targets and prognostic markers
in a wide spectrum of solid tumors. The present study
investigates the expression and prognostic value of four
FGFR family member proteins in a large multicenter oral
cavity squamous cell carcinoma (OCSCC) and oropha-
ryngeal squamous cell carcinoma (OPSCC) cohort.
Methods Protein expression of FGFR1–4 was determined by
immunohistochemistry on tissue microarrays containing 951
formalin-fixed paraffin embedded OCSCC and OPSCC tis-
sues from the University Medical Center Utrecht and
University Medical Center Groningen. Protein expression was
correlated to overall survival using Cox regression models,
and bootstrapping was performed as internal validation.
Results FGFR proteins were highly expressed in 39–64 %
of OCSCC and 63–79 % of OPSCC. Seventy-three percent
(299/412) of OCSCC and 85 % (305/357) of OPSCC
highly co-expressed two or more FGFR family member
proteins. FGFR1 protein was more frequently highly
expressed in human papillomavirus (HPV)-negative
OPSCC than HPV-positive OPSCC (82 vs. 65 %;
p = 0.008). Furthermore, protein expression of FGFR
family members was not related to overall survival in
OCSCC or OPSCC (p[ 0.05).
Conclusion FGFR family members are frequently highly
expressed in OCSCC and OPSCC. These FGFR family
member proteins are therefore potential targets for novel
therapies that are urgently required to improve survival of
OCSCC and OPSCC patients.
Key Points
FGFR family members have been identified as novel
therapeutic targets and prognostic markers in
multiple types of cancer.
In this study we found high expression of all four
FGFR family member proteins in large oral cavity
and oropharyngeal squamous cell carcinoma cohorts.
All four FGFR family member proteins may serve as
potential therapeutic targets.
Electronic supplementary material The online version of this
article (doi:10.1007/s40291-016-0204-5) contains supplementary
material, which is available to authorized users.
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1 Introduction
Despite improvements in diagnostic tools and treatment
regimens over the past three decades, overall survival rates
of advanced (stage III-IV) head and neck squamous cell
carcinoma (HNSCC) have only reached 65 % [1]. To
improve overall survival rates by means of a more indi-
vidualized treatment, new prognostic markers have been
identified for HNSCC and these are currently integrated
into HNSCC clinical trials. Prognostic markers include
Epstein-Barr virus (EBV) status, human papillomavirus
(HPV) status and PET-imaging features [2]. However,
despite these advancements, improvement of HNSCC
overall survival remains limited. Therefore, novel markers
are needed to select HNSCC patients for adjuvant therapy
and thereby improve overall survival rates. Generally,
HNSCC is treated by surgery and/or chemo-irradiation,
which cause severe side-effects in more than 80 % of the
advanced HNSCC patients [3]. Unfortunately, until now
other treatment options for HNSCC patients are limited to
only one single targeted therapy available in the clinic and
with variable benefit i.e. cetuximab, targeting epidermal
growth factor receptor (EGFR) protein [4]. To expand
personalized cancer care for HNSCC, novel targeted ther-
apies are needed [5].
For a wide spectrum of other types of cancer,
including lung, breast and colorectal cancer, multiple
targeted therapies have been developed and approved.
One of these targets for therapies and prognostic markers
recently identified, is the fibroblast growth factor recep-
tor (FGFR) protein family [4]. The FGFR family com-
prises four cell membrane bound tyrosine kinase
receptors (FGFR1–4) that activate multiple intracellular
signaling pathways. Genomic driver aberrations, such as
mutations, amplifications and translocations of FGFR1-4
genes dysregulate FGFR signaling pathways and promote
tumor development [6]. Targeting FGFR family members
with FGFR-inhibitors has shown promising therapeutic
value in clinical trials on breast, colorectal, thyroid and
non-small cell lung cancer [7, 8]. Although previous
studies have observed prognostic and therapeutic value
for FGFR family members, the expression and prognostic
value of all four FGFR family member proteins has not
been investigated in a cohort of HNSCC so far. To
assess their prognostic relevance, we investigated the
expression and prognostic value of all four FGFR family
member proteins in large cohorts of both oral cavity
squamous cell carcinoma (OCSCC) and oropharyngeal
squamous cell carcinoma (OPSCC).
2 Materials and Methods
2.1 Patient Cohorts
Inclusion criteria for the patient cohorts were: patients with
a first primary HNSCC of oral cavity or oropharyngeal
location who were treated with curative intent at the
University Medical Center Utrecht (UMCU) or University
Medical Center Groningen (UMCG) between the years
1996 and 2011 (Table 1). Exclusion criteria were: HNSCC
of nasopharyngeal, hypopharyngeal, or laryngeal location,
a previous history of HNSCC, a synchronous primary
tumor, histological abnormalities including dysplastic
lesions and inflammation, and the absence of tumor cores
on tissue microarray slides (TMA). Clinicopathological
data and follow-up data on patient overall survival were
retrieved from electronic medical records. Formalin-fixed
paraffin-embedded (FFPE) tissues of all tumors were col-
lected from pathology departments. OCSCC tissues inclu-
ded mainly surgical resection specimens and OPSCC
tissues included mainly pretreatment biopsy specimens.
Human tissues and patient data were used according to
‘‘The Code for Proper Secondary Use of Human Tissue’’
and ‘‘The Code of Conduct for the Use of Data in Health
Research’’ as stated by the Federation of Dutch Medical
Scientific Societies (Federa FMVV, updated 2011). All
slides and diagnoses were reviewed by a dedicated
pathologist (SMW). HPV status was determined for tumors
using a combination of p16 immunohistochemistry and a
PCR-based HPV-genotyping method as described previ-
ously [9, 10]. Using the reversed Kaplan–Meier method,
median follow-up time of OCSCC patients was
78.5 months and the median follow-up time of OPSCC
patients was 57 months.
2.2 Tissue Microarray Construction
FFPE tissues were constructed into tissue microarrays
using either the TMA Grand Master instrument (3D HIS-
TECH, Budapest, Hungary) in the UMCU or Manual Tis-
sue Arrayer I (Beecher Instruments, Sun Prairie, WI, USA)
in the UMCG. Construction of the UMCG-TMA was
reported previously [9, 11, 12]. Tumor areas of FFPE tis-
sues were marked by a pathologist (SMW) on the original
H&E slides. Three cores (0.6 mm) were punched from
tumor areas of each FFPE tissue and arrayed into a recip-
ient donor block. Normal placenta, liver, lung, stomach,
mammary, appendix, adrenal gland, colon and testis tissues
were included into TMAs for quality control of staining
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Table 1 Baseline characteristics of oral cavity squamous cell carcinoma and oropharyngeal squamous cell carcinoma patient cohorts from the
University Medical Center Utrecht and University Medical Center Groningen
UMCU UMCG OCSCC OPSCC p (OCSCC vs.
OPSCC)
Total no. of cases (n = 951) 452 (100) 499 (100) 512 (100) 439 (100)
Age
Median (range) 60 (26–88) 60 (24–94) 62 (24–94) 58 (35–89) 0.001
Gender
Male 295 (65) 312 (63) 305 (60) 302 (69) 0.003
Female 157 (35) 187 (37) 207 (40) 137 (31)
Clinical T-classification
cT1-cT2 213 (47) 261 (52) 310 (61) 164 (37) \0.001
cT3-cT4 238 (52.5) 227 (46) 191 (37) 274 (62)
Missing 1 (0.5) 11 (2) 11 (2) 1 (1)
Clinical N-classification
cN0 209 (46) 221 (44) 334 (65) 96 (22) \0.001
cN1-3 177 (39) 278 (56) 178 (35) 277 (63)
Missing 66 (15) 0 (0) 0 (0) 66 (15)
Clinical M-classification
cM0 407 (90) 353 (71) 401 (78) 359 (82) \0.001
cM1 11 (2.5) 4 (1) 0 (0) 15 (3)
Missing 34 (7.5) 142 (28) 111 (22) 65 (15)
Site
Oral cavity 212 (47) 300 (60) – – –
Oropharynx 240 (53) 199 (40) – – –
HPV status
Positive 45 (10) 53 (11) 9 (2) 89 (20) \0.001
Negative 398 (88) 414 (83) 475 (93) 337 (77)
Missing 9 (2) 32 (6) 28 (5) 13 (3)
Pathological T-classification
pT1-pT2 128 (28) 208 (42) 294 (57) 42 (10) 0.036
pT3-pT4 112 (25) 156 (31) 218 (43) 50 (11)
Missing 212 (47) 135 (27) 0 (0) 347 (79)
Pathological N-classification
pN0 104 (23) 158 (31.5) 233 (45.5) 29 (6.5) 0.001
pN1-3 129 (28.5) 198 (39.5) 266 (52) 61 (14)
Missing 219 (48.5) 143 (29) 13 (2.5) 349 (79.5)
Pathological stage
I-II 93 (21) 115 (23) 158 (31) 50 (11) \0.001
III-IV 346 (76) 384 (77) 354 (69) 376 (86)
Missing 13 (3) 0 (0) 0 (0) 13 (3)
Primary treatment
Surgery 273 (60) 371 (74) 512 (100) 132 (30) \0.001
(Chemo)radiotherapy 153 (34) 103 (20.5) 0 (0) 256 (58.5)
Palliative 26 (6) 23 (5) 0 (0) 49 (11)
Missing 0 (0) 2 (0.5) 0 (0) 2 (0.5)
Neck dissection
Yes 233 (51) 365 (73) 499 (97) 99 (22.5) \0.001
No 193 (43) 109 (22) 13 (3) 289 (66)
Palliative 26 (6) 23 (4.5) 0 (0) 49 (11)
Missing 0 (0) 2 (0.5) 0 (0) 2 (0.5)
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Table 1 continued
UMCU UMCG OCSCC OPSCC p (OCSCC vs.
OPSCC)
Postoperative (chemo)radiotherapy
Yes 104 (23) 268 (54) 283 (55) 89 (20) 0.012
No 169 (37) 103 (20.5) 229 (45) 43 (10)
Surgery not primary treatment 153 (34) 103 (20.5) 0 (0) 256 (58.5)
Palliative 26 (6) 23 (4.5) 0 (0) 49 (11)
Missing 0 (0) 2 (0.5) 0 (0) 2 (0.5)
Extra nodal growth
Yes 66 (14.5) 38 (7.5) 93 (18) 11 (2.5) 0.305
No 61 (13.5) 55 (11) 109 (21) 7 (1.5)
Not applicable 104 (23) 158 (31.5) 233 (46) 29 (7)
Missing 221 (49) 248 (50) 77 (15) 392 (89)
Lymphovascular invasion
Yes 52 (11.5) 44 (9) 69 (14) 27 (6) 0.023
No 206 (45.5) 288 (58) 405 (79) 89 (20)
Missing 194 (43) 167 (33) 38 (7) 323 (74)
Perineural growth
Yes 97 (21.5) 90 (18) 156 (30) 31 (7) 0.171
No 154 (34) 262 (53) 327 (64) 89 (20)
Missing 201 (44.5) 147 (29) 29 (6) 319 (73)
Bone invasion
Yes 64 (14) 60 (12) 119 (23) 5 (1) 0.001
No 176 (39) 20 (4) 191 (37) 30 (7)
Missing 212 (47) 419 (84) 202 (40) 404 (92)
Growth pattern
Cohesive 55 (12) 5 (1) 49 (10) 11 (2.5) 0.102
Non-cohesive/invasive 200 (44) 105 (21) 272 (53) 33 (7.5)
Missing 197 (44) 389 (78) 191 (37) 395 (90)
Infiltration depth
0–4 mm 21 (5) 32 (7) 50 (10) 3 (0.5) 0.211
[4 mm 219 (48) 161 (32) 337 (66) 43 (10)
Missing 212 (47) 306 (61) 125 (24) 393 (89.5)
Differentiation grade
Well/moderate 189 (42) 260 (52) 416 (81) 33 (7.5) 0.007
Poor/undifferentiated 50 (11) 51 (10) 85 (17) 16 (3.5)
Missing 213 (47) 188 (38) 11 (2) 390 (89)
Overall survival time (months)
Median (range) 43.5 (0–185) 33 (0–167) 43 (0–185) 27 (0–168) \0.001
Overall survival status
Alive 185 (41) 296 (59) 278 (54) 202 (46) 0.026
Dead 241 (53) 175 (35) 230 (45) 186 (42.5)
Palliative 26 (6) 23 (5) 0 (0) 49 (11)
Missing 0 (0) 5 (1) 4 (1) 2 (0.5)
The cohorts comprised oral cavity and oropharyngeal squamous cell carcinoma patients, who were treated in these hospitals between the year
1996 and 2011. Clinicopathological characteristics of all patients were retrieved from electronic medical records and formalin fixed paraffin-
embedded tissues of all tumors were collected. The human papillomavirus type (HPV) status was determined using P16 immunohistochemistry
and a PCR-based HPV-genotyping method
HPV human papillomavirus, OCSCC oral cavity squamous cell carcinoma, OPSCC oropharyngeal squamous cell carcinoma, UMCG University
Medical Center Groningen, UMCU University Medical Center Utrecht
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[13]. Normal healthy tonsillar and oral mucosa tissues were
included in all TMAs. These tissues were collected from
healthy individuals who have no history of HNSCC.
2.3 Immunohistochemistry
To determine FGFR family member protein expression,
immunohistochemistry was performed on TMA slides with
a BenchMark ULTRA automated staining instrument
(Ventana Medical Systems, Tucson, AZ, USA). Slides
were mechanically deparaffinized, pretreated with EDTA
and rinsed with reaction buffer. Next, sets of slides were
incubated with 150 lL anti-FGFR1 antibody (ab10646,
1:2000 dilution) (Abcam, Cambridge, UK), anti-FGFR2
antibody (ab10648, 1:1000 dilution) (Abcam), anti-FGFR3
antibody (sc-13121, 1:25 dilution) (Santa Cruz Biotech-
nology, Dallas, TX, USA) or anti-FGFR4 antibody
(PAB3044, 1:200 dilution) (Abnova, Taipei City, Taiwan)
for 32 min. Prior to staining TMA slides, staining methods
were optimized by testing antibodies for pretreatments
EDTA, citrate, pepsine, or no pretreatment with dilutions
ranging from 1:10 to 1:2000. Antibody specificity to the
corresponding FGFR protein was verified by testing them
on the following positive and negative controls; placenta
and stomach for FGFR1, lung and pancreas for FGFR2,
liver and stomach for FGFR3, and stomach and lung for
FGFR4 [13]. After rinsing with reaction buffer, slides were
incubated with Optiview HQ Universal Linker and Opti-
view HRP multimer (Ventana Medical Systems) for eight
min. Finally, diaminobenzidine was applied and slides
were counterstained with hematoxylin.
To semi-quantify FGFR1-4 protein expression, the per-
centage of positively stained tumor cells (0–100 %) and
staining intensity (negative/normal healthy tissue 0, mod-
erate ?1, strong ?2) were scored in OCSCC and OPSCC.
FGFR1–4 staining in OCSCC and OPSCC was compared to
staining in normal healthy tonsillar and oral mucosa tissues.
Staining in these normal tissues was used as a reference. All
TMA cores were scored by a dedicated head and neck
pathologist (SMW) and head and neck researchers (KK and
MJAMC) together. All three observers were blinded to the
outcome of patients. Discordant cases were discussed until
consensus was reached. For FGFR3, only the staining
intensity was scored as the percentage of stain-positive
tumor cells was always 100 % and thus not discriminative.
For each tumor, mean percentages and maximum stain
intensities were computed from available TMA cores.
Tumors with only one or two TMA cores available were
included in the analysis. Continuous percentage scores were
dichotomized by cutoff values, which were optimized for
predicting patient overall survival using log-likelihood
values. Optimizing cutoff values on patient outcome using
log-likelihood values has been described as the appropriate
method in previous studies [14]. Cutoff values for both
OCSCC and OPSCC were 10 % for FGFR1, 15 % for
FGFR2 and 33 % for FGFR4. Other cutoff values and the
staining intensity for FGFR1, FGFR2 and FGFR4 were
much less optimal in predicting overall survival (data not
shown) and were not further used in this study. For FGFR3,
?1 intensity was selected as a cutoff value, with 0 defined
as low/negative expression and ?1 and above defined as
high expression. Co-expression of FGFR family member
proteins was only evaluated in tumors for which data on all
four FGFRs were available as for some tumors TMA cores
were missing. Co-expression was defined as concurrent
high expression of two or more FGFR family member
proteins in a single tumor.
2.4 Statistical Analysis
Data were analyzed using IBM SPSS Statistics version 22
software (IBM, Amonk, NY, USA). Baseline characteris-
tics and protein expression were compared between
OCSCC and OPSCC using Pearson’s chi square test for
dichotomous variables and t-test for continuous variables.
Patients who were treated with curative intent were
included and patients who were treated with palliative
intent were excluded from overall survival analysis. Uni-
variate Kaplan-Meier overall survival curves were plotted
and compared with a log-rank test to analyze the rela-
tionships between protein expression of FGFR family
members and overall survival. Significant relationships for
FGFR1 expression and FGFR1–4 co-expression were fur-
ther analyzed by multivariate Cox regression. Covariates
were detected by analyzing relationships between variables
and overall survival, and confounders were detected by
analyzing variables in relation to FGFR expression and
overall survival. Covariates and confounders included in
both multivariate models were: clinical T-classification,
clinical N-classification, pathological T-classification,
pathological N-classification, extra nodal growth, lym-
phovascular invasion, perineural growth, growth pattern
and pathological stage. Postoperative (chemo)radiotherapy
was identified as an effect modifier for FGFR1–4 protein
co-expression, and corrected for in the model. Internal
validation of the (bio)marker-based risk prediction model
was performed by bootstrapping based on 5000 samples.
Splitting the study cohort in a development and validation
cohort was not the preferred validation method, because it
is statistically inefficient to only use a subset of all data to
produce the prediction model and it is accompanied by
replication instability, as described by Moons et al. [15].
Two-sided p values below 0.05 were considered significant
throughout all statistical computations. The p values were
corrected for multiple-comparison by calculating Bonfer-
roni-corrected p values as appropriate. Finally, Python
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Fig. 1 Representative microscopic images of immunohistochemical
staining for FGFR family member proteins in oral cavity squamous
cell carcinoma and normal healthy oral mucosa tissue microarray
cores (910 and 940 magnification). a–d Strong immunohistochem-
ical staining indicating high FGFR1, FGFR2, FGFR3 and FGFR4
protein expression in oral cavity squamous cell carcinoma. e No
immunohistochemical staining indicating absence of FGFR1–4
protein expression in oral cavity squamous cell carcinoma. f Faint
immunohistochemical staining indicating low expression of
FGFR1–4 protein in normal healthy oral mucosa tissue. Protein
expression was determined immunohistochemically using anti-
FGFR1–4 antibodies in a cohort of oral cavity squamous cell
carcinoma (n = 512) and oropharyngeal squamous cell carcinoma
(n = 439). FGFR fibroblast growth factor receptor
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version 2.7 was used to analyze co-high expression data




The UMC Utrecht cohort included 212 OCSCC and 240
OPSCC patients and the UMC Groningen cohort included
300 OCSCC and 199 OPSCC patients. Altogether, the total
cohort comprised 512 OCSCC patients and 439 OPSCC
patients. Twenty-one percent (89/426) of OPSCC were
HPV-positive, 79 % (337/426) HPV-negative, and 3 % (13/
439) were not tested for HPV. Thirty-one percent (158/512)
of OCSCC were early (stage I–II) tumors and 69 % (354/
512) advanced (stage III–IV) tumors. Twelve percent (50/
426) of OPSCC were early (stage I–II) tumors and 88 %
(376/426) advanced (stage III–IV) tumors, and pathological
stage was missing in 3 % (13/439) of OPSCC. One hundred
percent (512/512) of OCSCC were treated with surgery,
97 % (499/512) received a neck dissection and 55 % (283/
512) received postoperative (chemo)radiotherapy. Thirty
percent (132/437) of OPSCC were treated with surgery,
59 % (256/437) with (chemo)radiotherapy, 11 % (49/437)
were treated with palliative intent, and the type of primary
treatment was missing in 0.5 % (2/439). Twenty-three per-
cent (99/437) of OPSCC received a neck dissection and 20 %
(89/437) received postoperative (chemo)radiotherapy.
Table 1 summarizes the clinicopathological and follow-up
data of the OCSCC and OPSCC cohorts.
3.2 FGFR1-4 Proteins are Frequently High
Expressed and Co-Expressed in Oral Cavity
and Oropharyngeal Squamous Cell Carcinoma
Representative images of FGFR proteins high expressed
and low expressed in OCSCC and OPSCC are shown in
Fig. 1a–e. Mainly cytoplasmic staining was observed, as
reported in gastric cancer [16]. Faint FGFR1–4 staining of
0 intensity was observed in all normal healthy oral mucosa
and tonsillar tissues, indicating low expression found in
these tissues (Fig. 1f). Strong staining for FGFR family
member proteins was noted in corresponding positive
controls and absence of staining was noted in corre-
sponding negative controls.
FGFR proteins were highly expressed in 39–64 % of
OCSCC (FGFR4 and FGFR1 respectively) and 63–79 % of
OPSCC (FGFR3 and FGFR1 respectively) (Fig. 2 and
Supplementary Table S1). High protein expression was more
common in OPSCC than OCSCC for all four FGFR family
members (FGFR1–4: p = 0.008). Within the OPSCC
population, FGFR1 protein was highly expressed more fre-
quently in HPV-negative than in HPV-positive OPSCC (82
vs. 65 %; p = 0.008). Expression of FGFR proteins was
missing for a subgroup of OCSCC and OPSCC because all
three TMA cores were missing (Supplementary Table S1).
Furthermore, two or more FGFR proteins were highly
co-expressed in 73 % (299/412) of OCSCC and 85 % (305/
357) of OPSCC (Fig. 3). FGFR1/2 were most frequently
highly co-expressed in OCSCC (13 %; 55/412) and
FGFR1–4 in OPSCC (28 %; 101/357). Within the OPSCC
population, FGFR2/3 were more frequently highly co-ex-
pressed in HPV-positive compared to HPV-negative
OPSCC (5 % (4/73) versus 0.4 % (1/275); OR 15.81; 95 %
CI 1.75–143; p = 0.014) but lost significance after cor-
recting for multiple testing. Expression of one or more
FGFR proteins was missing in 20 % (100/512) of OCSCC
and 19 % (82/439) of OPSCC because all three TMA cores
were missing for these tumors.
3.3 High FGFR Expression is Not Related to Poor
Overall Survival in Oral Cavity
and Oropharyngeal Squamous Cell Carcinoma
High FGFR1 expression (p = 0.018) and high FGFR1–4
co-expression (0.030) was related to poor overall survival
in OCSCC in univariate analysis, but lost significance in
multivariate models (FGFR1: OR 1.46; 95 % CI
0.91–2.34; p = 0.690, FGFR1–4: OR: 2.44; 95 % CI
1.29–5.50; p = 0.060) (Table 2; Fig. 4). All other FGFR
Fig. 2 Expression of FGFR1–4 protein sorted by head and neck
cancer site and HPV status. FGFR1–4 protein expression was
determined immunohistochemically in a cohort of oral cavity
squamous cell carcinoma (n = 512) and oropharyngeal squamous
cell carcinoma (n = 439) from the University Medical Center Utrecht
and University Medical Center Groningen. FGFR1–4 proteins were
high expressed in 39–64 % of oral cavity squamous cell carcinoma
and 63–79 % of oropharyngeal squamous cell carcinoma. High
protein expression was more common in oropharyngeal squamous
cell carcinoma than oral cavity squamous cell carcinoma for all four
FGFR family members (p = 0.008). FGFR1 protein was high
expressed much more frequently in HPV-negative than in HPV-
positive oropharyngeal squamous cell carcinoma (82 vs. 65 %;
p = 0.008). FGFR fibroblast growth factor receptor, HPV human
papillomavirus, OPSCC oropharyngeal squamous cell carcinoma,
OCSCC oral cavity squamous cell carcinoma
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family members were not related to overall survival in
OCSCC, OPSCC, HPV-positive OPSCC and HPV-nega-
tive OPSCC (Table 2; Fig. 4, Supplementary Fig. 1).
Expression of FGFR family member proteins was not
related to pathological stage (p[ 0.05).
4 Discussion
We identified frequent high expression of all four FGFR
family member proteins in large cohorts of OCSCC and
OPSCC, with significant higher expression rates in
OPSCC. Previous studies have reported high FGFR1 and
FGFR4 expression in HNSCC but at much lower rates of
12 % for FGFR1 by Freier et al. and 16 % for FGFR4 by
Streit et al., compared to 64 and 39 % in this study
[17–20]. Disagreements in high expression rates between
studies could be explained by the use of different cutoff
values, antibodies and patient cohorts.
In this study, no prognostic value was observed for
protein expression of FGFR family members in OCSCC
and OPSCC. This is in contrast to the prognostic value
reported for FGFR4 in HNSCC and other FGFR family
members in multiple types of cancer including gastric,
Fig. 3 Venn diagrams of high FGFR1–4 protein co-expression sorted
by head and neck cancer site and HPV status. FGFR1–4 protein
expression was determined immunohistochemically in a cohort of
oral cavity squamous cell carcinoma (n = 512) and oropharyngeal
squamous cell carcinoma (n = 439). FGFR1 protein was highly
expressed more frequently in HPV-negative than in HPV-positive
oropharyngeal squamous cell carcinoma (82 vs. 65 %; p = 0.008).
Furthermore, FGFR2/3 were more frequently highly co-expressed in
HPV-positive compared to HPV-negative oropharyngeal squamous
cell carcinoma [5 % (4/73) vs. 0.4 % (1/275); OR 15.81; 95 % CI
1.75–143; p = 0.014], but lost significance after correcting for
multiple testing. Co-expression was only assessed in samples in
which expression data for all four FGFR family members was
available. Co-expression was defined as concurrent high expression of
two or more FGFR family member proteins in a single tumor. FGFR
fibroblast growth factor receptor, HPV human papillomavirus,
OPSCC oropharyngeal squamous cell carcinoma, OCSCC oral cavity
squamous cell carcinoma
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colorectal, bladder and esophageal cancer [16, 21–25]. In
this study, cutoff values for FGFR expression were selected
on the value best predicting overall survival outcome.
Cutoff values were computed from the same dataset as the
results on overall survival were retrieved, by which the
observed effects are overestimated. Overestimation of the
effects has been corrected for by internal validation, but
further external validation on a different cohort is neces-
sary. Secondly, our findings on protein expression of FGFR
family members should be confirmed in future studies
using other laboratory methods than immunohistochem-
istry with antibodies.
Interestingly, in our study FGFR1-4 proteins are fre-
quently highly co-expressed in HNSCC, which is in line
with similar findings in gastric cancer [25]. The high fre-
quency of FGFR co-expression suggests therapeutic value
for FGFR-inhibitors in OCSCC and OPSCC that target
multiple FGFR family member proteins. Currently, the
most impressive anti-tumor activity has been reported for
non-selective tyrosine kinase inhibitors (TKI) but they
cause more adverse effects due to vascular endothelial
growth factor (VEGF) inhibition. Conversely, selective
FGFR-inhibitors show less anti-tumor activity but fewer
adverse effects [6]. Selective FGFR-inhibitors are widely
available for FGFR1–3 and only recently available for
FGFR4 [26, 27]. Therapeutic value has already been
observed for the FGFR1-inhibitor PD173074 in HNSCC
cell lines and a clinical trial on HNSCC patients with the
FGFR-inhibitor ponatinib has been completed [28] (Clini-
calTrials.gov Identifier: NCT01761747).
Remarkably, FGFR1 protein was more frequently highly
expressed in HPV-negative than HPV-positive OPSCC.
This may reflect the FGFR1-driven tumor biology of HPV-
negative OPSCC and could identify a specific subgroup
sensitive to FGFR1-inhibitor therapy. Several studies have
reported genomic aberrations of FGFR1/2/3 unique for
HPV-positive or HPV-negative HNSCC and a direct rela-
tion between HPV oncogenes E6/7 and the beta-variants of
FGFR1–4 expression in five cancer cell lines [29–31]. In
these studies, they observed that FGFR1 amplification was
Table 2 Multivariate overall
survival Cox regression analysis
for protein expression of FGFR
family members in oral cavity
and oropharyngeal squamous
cell carcinoma after internal
validation by bootstrapping and
Bonferroni correction
Protein (co-)expression HR 95 % CI p HR 95 % CI p
OCSCC (n = 508) OPSCC (n = 388)
FGFR1 1.46 0.91–2.34 0.690 1.42 0.93–2.16 0.648
FGFR2 2.03 0.64–5.23 0.408 1.02 0.75–1.40 1.000
FGFR3 1.22 0.92–1.63 0.966 1.09 0.79–1.50 1.000
FGFR4 1.20 0.75–1.91 1.000 1.13 0.81–1.57 1.000
FGFR1–2 1.04 0.67–1.61 1.000 0.71 0.31–1.61 1.000
FGFR1–4 2.44 1.29–5.50 0.060 1.05 0.74–1.49 1.000
HPV-positive OPSCC (n = 80) HPV-negative OPSCC (n = 295)
FGFR1 1.85 0.52–6.56 1.000 1.21 0.75–1.93 1.000
FGFR2 1.23 0.38–3.91 1.000 1.06 0.76–1.47 1.000
FGFR3 1.00 0.34–2.94 1.000 1.16 0.82–1.63 1.000
FGFR4 0.72 0.23–2.27 1.000 0.83 0.38–1.82 1.000
FGFR1–2 35.44 4.89–256.84 0.006a 0.30 0.09–0.93 0.228a
FGFR1–4 1.03 0.34–3.06 1.000 2.20 0.49–9.85 1.000
Associations between protein expression of FGFR family members and overall survival were analyzed
using Cox regression. Significant relationships were further analyzed by multivariate Cox regression
models. Covariates and confounders were identified and included in multivariate models. For the rela-
tionship between FGFR1–4 protein co-expression and overall survival, postoperative chemotherapy or
chemoradiotherapy was identified as an effect modifiers and corrected for in the model. Internal validation
of (bio)marker-based risk prediction models was performed by bootstrapping based on 5000 samples
Throughout these statistical computations, two-sided p values below 0.05 were considered significant.
Cutoff values for protein expression of FGFR family members were optimized on predicting patient
outcome. Cutoff values were 10 % for FGFR1, 15 % for FGFR2, ?1 intensity for FGFR3 and 33 % for
FGFR4. Overall survival status was missing for four oral cavity and two oropharyngeal squamous cell
carcinoma patients and HPV status was missing for 13 oropharyngeal squamous cell carcinoma patients.
Forty-nine oropharyngeal squamous cell carcinoma patients were excluded from survival analysis because
they were treated with palliative intent
95 % CI 95 % confidence interval, FGFR fibroblast growth factor receptor, HPV human papillomavirus,
HR hazard ratio, OPSCC oropharyngeal squamous cell carcinoma, OCSCC oral cavity squamous cell
carcinoma
a Too few cases were available (FGFR1–2 co-high expression: HPV-positive OPSCC: 2 cases and HPV-
negative OPSCC: 3 cases)
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much more common in HPV-negative HNSCC, while
FGFR2 and FGFR3 aberrations were much more common
in HPV-positive HNSCC [29, 30]. Also in cervical squa-
mous cell carcinoma, all tumors harboring FGFR3 muta-
tions were HPV-positive [32]. These genomic findings
reflect the FGFR1-driven tumor biology of HPV-negative
and FGFR2/3-driven tumor biology of HPV-positive
HNSCC. The therapeutic implications regarding sensitivity
to targeted therapies may correspond accordingly. As such,
our findings on protein level are comparable to genomic
findings in literature. So far, clinical trials focus on FGFR
genomic aberrations to predict response of HNSCC to
FGFR-inhibitors (ClinicalTrials.gov Identifier:
NCT01761747). But these predictive markers should be
revised, as FGFR1 mRNA and protein expression, rather
than FGFR1 gene copy-number status, predicted response
of HNSCC cell lines to FGFR-inhibitor BGJ398 in a recent
report [33].
Fig. 4 Kaplan–Meier overall survival curves for FGFR1 and FGFR2
protein expression and FGFR1–4 protein co-expression in oral cavity
and oropharyngeal squamous cell carcinoma. a High FGFR1
(p = 0.018) protein expression and b high FGFR1–4 (p = 0.030)
co-expression were related to poor overall survival in oral cavity
squamous cell carcinoma in univariate analysis, but lost significance
in multivariate analysis (FGFR1: HR 1.46; 95 % CI 0.91–2.34;
p = 0.690, high expression: 151/305 died, low expression: 64/172
died, FGFR1–4: HR 2.44; 95 % CI 1.29–5.50; p = 0.060, high
expression: 25/37 died, low expression: 165/399 died). c–f High
FGFR2 (P = 0.084) protein expression was not related to overall
survival in oral cavity squamous cell carcinoma (high expression:
118/238 died, low expression: 94/239 died). High FGFR1
(p = 0.630) expression, high FGFR1–4 (p = 1.000) co-expression
and high FGFR2 (p = 1.000) expression were not related to overall
survival in oropharyngeal squamous cell carcinoma (FGFR1: high
expression: 148/287 died, low expression: 25/76 died, FGFR1–4: high
expression: 45/88 died, low expression: 107/224 died and FGFR2:
high expression: 107/225 died, low expression: 61/127 died)
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In conclusion, FGFR family members are frequently
overexpressed in HNSCC, especially in OPSCC, and
expression varies in subpopulations of OCSCC and
OPSCC. FGFR family member proteins are therefore
potential targets for novel targeted therapies that are
urgently needed to improve survival of OCSCC and
OPSCC patients.
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